From Liston Street Pulse:
Shares of Vical Incorporated (VICL) have plunged in trading today after the company reported negative clinical trial results. Vical, which is engaged in the research and development of biopharmaceutical products based on its DNA delivery technologies, said that top-line results from its Phase 3 trial of Allovectin® failed to meet efficacy endpoints. Vijay B. Samant, […]
The post Vical Incorporated Tumbles appeared first on Liston Street Pulse.
Created by Stock Researching | Dec 13, 2016
Created by Stock Researching | Dec 04, 2016
Created by Stock Researching | Dec 02, 2016
Created by Stock Researching | Nov 19, 2016
Created by Stock Researching | Nov 10, 2016
Created by Stock Researching | Oct 05, 2015